and servo motors. We target applications in wearable robotics, exoskeletons, and humanoid robots—delivering scalable, modular solutions for industries ranging from healthcare and rehabilitation to industrial ergonomics. Our flagship technology is currently at TRL 4 and supported by national and international patents (PCT, USPTO). Vexnor has secured equity-based public funding through the TUBITAK 1812 Investment Program, a joint initiative by TUBITAK and the Türkiye Development Fund, and received additional support from KOSGEB. The company was awarded during its pre-incubation phase from Manisa Teknokent and received the TUBIAK "Seal of Excellence", validating the project’s scientific, technical, and commercial merit. With mentoring from Sabancı University’s SUCool program, Vexnor successfully transitioned into an incorporated company. It is also backed by a strong advisory board and academic collaborations. Our business model includes B2B actuator sales, licensing of our proprietary Magneruca core technology, and vertical product lines like the Myospine wearable solution. We aim to pioneer the next generation of human-machine interfaces and artificial muscle platforms—accelerating the roadmap through upcoming investment and public funding, with the goal of global deployment by 2026.

Keywords: Biomimetic Actuators, Wearable Robotics, Exoskeleton Technology, Artificial Muscles, Human-Machine Integration, Assistive Robotics, Industrial Ergonomics, Electromechanical Systems, HealthTech, DeepTech, Biomechanics, Robotics R&D, MedTech